Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients

• Status: Recruiting
• Trial end date: 2021-10-30
• Target enrollment: 0
• Participant gender: All

Summary

To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sohaib Ashraf
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• Nasopharyngeal RT-PCR positive SARS-CoV-2 patient with mild to moderate disease

• Age 18 and above

• BMI 18-28 kg/m

Exclusion Criteria:

• Allergy to any drug

• Co-morbidities: any pre-existing cardiac disease, pulmonary disease

• Arrhythmias

• Pregnancy

• RT-PCR performed >3 days prior to enrollment